The FDA rolled out an expedited Investigational New Drug (IND) pilot program designed to address bottlenecks in early clinical trial entry. The initiative, part of HHS’s effort to onshore clinical trials, was framed as reducing delays by applying risk-proportionate, phase-appropriate judgment and running processes in parallel rather than sequentially. According to the program description, the IND review standards and timelines remain the same, but the submission preparation path is intended to be more efficient. The HHS named the effort “Operation TrialBlazer,” aligning with broader directives to accelerate timelines from drug discovery to first-in-human studies. Experts quoted in the report noted that while such pilots may help, incentives to onshore trials still depend on comparative timelines and trial recruitment speed in other regions.